Trevi’s chronic cough drug surpasses expectations in mid-stage trial

Trevi Therapeutics (Nasdaq: TRVI) has reported promising results from a mid-stage study of its experimental chronic cough treatment, Haduvio (nalbuphine extended-release). Shares in the company are trading around a third higher following the announcement.

In the Phase IIa RIVER trial, Haduvio reduced 24-hour cough frequency by 57% compared to placebo. Among those with severe baseline cough in the small trial, the reduction reached 66%.

Trevi chief executive Jennifer Good highlighted Haduvio’s potential to become a best-in-class treatment for RCC, pointing to the limited treatment options available. She noted that the competitive landscape has narrowed in recent years following multiple trial failures.